Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | GLA | P06280 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571830 | 0.75 | CDK4 (0.41) | CDK4CCND1ALDH1A1KDM4EGLA | |
| SCHEMBL30472831 | 0.75 | TOP2A (0.44) | CDK4CCND1ALDH1A1KDM4EHPGD | |
| SCHEMBL5476684 | 0.75 | KDM4E (0.52) | CDK4CCND1ALDH1A1KDM4EGLA | |
| SCHEMBL11690096 | 0.74 | ALDH1A1 (0.58) | CDK4CCND1ALDH1A1KDM4EGLA | |
| SCHEMBL30853545 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL29712310 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL297515 | 0.74 | ALDH1A1 (0.58) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| SCHEMBL10944923 | 0.74 | ALDH1A1 (0.61) | CDK4CCND1ALDH1A1KDM4EGLA | |
| SCHEMBL17099903 | 0.72 | ALDH1A1 (0.56) | ALDH1A1KDM4EGLAHPGDHSD17B10 | |
| Iodide SCHEMBL10805145 | 0.72 | ALDH1A1 (0.56) | ALDH1A1KDM4EGLAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375530-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LTD (GB) | 2025-12-11 | — | — | US | claimed |
| EP-4638722-A2 | ALPP-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2025-10-29 | — | — | EP | claimed |
| EP-4543489-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2025-04-30 | — | — | EP | claimed |
| WO-2024133763-A2 | ALPP-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2024-06-27 | — | — | WO | claimed |
| WO-2023247729-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2023-12-28 | — | — | WO | claimed |
| WO-2023247731-A1 | ROR1/PTK7 BI-SPECIFIC ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LIMITED (GB) | 2023-12-28 | — | — | WO | claimed |
| US-7388026-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN, INC. (US) | 2008-06-17 | — | — | US | claimed |
| US-20060009462-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2006-01-12 | — | — | US | claimed |
| US-12616750-B2 | Combination therapy utilizing DNA alkylating agents and ATR inhibitors | MERCK PATENT GMBH (DE) | 2026-05-05 | — | — | US | disclosed |
| EP-4701666-A1 | ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | Iksuda Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20250375530-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | ALMAC DISCOVERY LTD (GB) | 2025-12-11 | — | — | US | disclosed |
| EP-4638722-A2 | ALPP-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES | Almac Discovery Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250255979-A1 | PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES | IMMUNOGEN, INC. | 2025-08-14 | — | — | US | disclosed |
| WO-2003086318-A2 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003087055-A1 | IMPROVED CC-1065 ANALOG SYNTHESIS | IMMUNOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195365-A1 | CC-1065 analog synthesis | IMMUNOGEN INC. | 2003-10-16 | — | — | US | disclosed |
| US-6586618-B1 | Amination 1,3-dihydoxynaphthalene, then blocking, iodination, alkylation, cyclization and deblocking to give (5-hydroxy-3-amino-1-(S)-(chloromethyl)-1,2-dihydro-3H-benz(e)indole), used as chemical intermediates of antitumor agents | IMMUNOGEN INC. | 2003-07-01 | — | — | US | disclosed |
| US-6534660-B1 | Halogenation, alkylation and ring-closure of protected 2-amino-4-hydroxynaphthalene under suitable conditions to provide desired racemate, isolating (-) isomer, removing protecting groups | IMMUNOGEN, INC. | 2003-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255979-A1 | PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES | EPCAM, CD44, NAPA | CDK4 1063/4885CCND1 1956/4885ALDH1A1 558/4885 |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | CDK4 1045/4885CCND1 2196/4885ALDH1A1 2482/4885 |
| US-20250375530-A1 | ROR1/EGFR BI-SPECIFIC ANTIGEN BINDING MOLECULES | EGFR, ROR1, ERBB2 | CDK4 3308/4885CCND1 4019/4885ALDH1A1 2032/4885 |
| US-20060009462-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | CDK4 1045/4885CCND1 2196/4885ALDH1A1 2482/4885 |
| US-20030195365-A1 | CC-1065 analog synthesis | DCUN1D5, DCUN1D1, DBN1 | CDK4 730/4885CCND1 1487/4885ALDH1A1 319/4885 |
| US-12616750-B2 | Combination therapy utilizing DNA alkylating agents and ATR inhibitors | ATR, MRE11, CHEK2 | CDK4 136/4885CCND1 660/4885ALDH1A1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.